Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms
Portfolio Pulse from
Oncocyte Corp. announced that its lead assay, VitaGraft™, can detect kidney transplant rejection over 11 months earlier than standard protocols, according to a new study published in Nephrology Dialysis Transplantation.
December 02, 2024 | 9:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oncocyte Corp.'s VitaGraft™ assay shows significant advancement in detecting kidney transplant rejection much earlier than standard protocols, potentially boosting the company's market position.
The new study highlights the effectiveness of Oncocyte's VitaGraft™ assay in early detection of kidney transplant rejection, which could lead to increased adoption and sales, positively impacting OCX's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100